To include your compound in the COVID-19 Resource Center, submit it here.

Raising KRAS

How Wellspring, Janssen team showed potential of KRAS inhibitor for cancer

For the first time, a joint research team from Wellspring Biosciences LLC and the Janssen Research & Development unit of Johnson & Johnson (NYSE:JNJ) showed a small molecule K-Ras (KRAS) inhibitor worked in animal models of cancer. The results could pave the way for clinical development of a therapy against the target, a member of the notoriously “undruggable”

Read the full 583 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers